FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:CPEB2-ATP8A1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: CPEB2-ATP8A1
FusionPDB ID: 18954
FusionGDB2.0 ID: 18954
HgeneTgene
Gene symbol

CPEB2

ATP8A1

Gene ID

132864

10396

Gene namecytoplasmic polyadenylation element binding protein 2ATPase phospholipid transporting 8A1
SynonymsCPE-BP2|CPEB-2|hCPEB-2ATPASEII|ATPIA|ATPP2
Cytomap

4p15.32

4p13

Type of geneprotein-codingprotein-coding
Descriptioncytoplasmic polyadenylation element-binding protein 2CPE-binding protein 2phospholipid-transporting ATPase IAATPase IIATPase class I type 8A member 1ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1P4-ATPase flippase complex alpha subunit ATP8A1aminophospholipid translocasechromaffin granule ATPase
Modification date2020031320200329
UniProtAcc

Q7Z5Q1

Main function of 5'-partner protein: FUNCTION: May play a role in translational regulation of stored mRNAs in transcriptionally inactive haploid spermatids. Binds to poly(U) RNA oligomers (By similarity). Required for cell cycle progression, specifically for the transition from metaphase to anaphase (PubMed:26398195). {ECO:0000250|UniProtKB:Q812E0, ECO:0000269|PubMed:26398195}.

Q9Y2Q0

Main function of 5'-partner protein: FUNCTION: Catalytic component of a P4-ATPase flippase complex which catalyzes the hydrolysis of ATP coupled to the transport of aminophospholipids from the outer to the inner leaflet of various membranes and ensures the maintenance of asymmetric distribution of phospholipids (PubMed:31416931). Phospholipid translocation seems also to be implicated in vesicle formation and in uptake of lipid signaling molecules. In vitro, its ATPase activity is selectively and stereospecifically stimulated by phosphatidylserine (PS) (PubMed:31416931). The flippase complex ATP8A1:TMEM30A seems to play a role in regulation of cell migration probably involving flippase-mediated translocation of phosphatidylethanolamine (PE) at the plasma membrane (By similarity). Acts as aminophospholipid translocase at the plasma membrane in neuronal cells (By similarity). {ECO:0000250|UniProtKB:P70704, ECO:0000269|PubMed:31416931}.
Ensembl transtripts involved in fusion geneENST idsENST00000259997, ENST00000345451, 
ENST00000382395, ENST00000382401, 
ENST00000442003, ENST00000507071, 
ENST00000538197, ENST00000541112, 
ENST00000510289, ENST00000264449, 
ENST00000381668, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score2 X 1 X 2=45 X 5 X 3=75
# samples 25
** MAII scorelog2(2/4*10)=2.32192809488736log2(5/75*10)=-0.584962500721156
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: CPEB2 [Title/Abstract] AND ATP8A1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: CPEB2 [Title/Abstract] AND ATP8A1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)CPEB2(15009210)-ATP8A1(42509171), # samples:1
Anticipated loss of major functional domain due to fusion event.CPEB2-ATP8A1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
CPEB2-ATP8A1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
CPEB2-ATP8A1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
CPEB2-ATP8A1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneCPEB2

GO:0032869

cellular response to insulin stimulus

18752464

HgeneCPEB2

GO:0071456

cellular response to hypoxia

18752464



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr4:15009210/chr4:42509171)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across CPEB2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across ATP8A1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000442003CPEB2chr415009210+ENST00000381668ATP8A1chr442509171-77621671032181072
ENST00000442003CPEB2chr415009210+ENST00000264449ATP8A1chr442509171-77581671032181072
ENST00000538197CPEB2chr415009210+ENST00000381668ATP8A1chr442509171-80351944034911163
ENST00000538197CPEB2chr415009210+ENST00000264449ATP8A1chr442509171-80311944034911163
ENST00000541112CPEB2chr415009210+ENST00000381668ATP8A1chr442509171-80351944034911163
ENST00000541112CPEB2chr415009210+ENST00000264449ATP8A1chr442509171-80311944034911163
ENST00000507071CPEB2chr415009210+ENST00000381668ATP8A1chr442509171-6811720872267726
ENST00000507071CPEB2chr415009210+ENST00000264449ATP8A1chr442509171-6807720872267726
ENST00000345451CPEB2chr415009210+ENST00000381668ATP8A1chr442509171-6811720872267726
ENST00000345451CPEB2chr415009210+ENST00000264449ATP8A1chr442509171-6807720872267726
ENST00000259997CPEB2chr415009210+ENST00000381668ATP8A1chr442509171-6773682492229726
ENST00000259997CPEB2chr415009210+ENST00000264449ATP8A1chr442509171-6769682492229726
ENST00000382401CPEB2chr415009210+ENST00000381668ATP8A1chr442509171-6500409491956635
ENST00000382401CPEB2chr415009210+ENST00000264449ATP8A1chr442509171-6496409491956635
ENST00000382395CPEB2chr415009210+ENST00000381668ATP8A1chr442509171-6773682492229726
ENST00000382395CPEB2chr415009210+ENST00000264449ATP8A1chr442509171-6769682492229726

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000442003ENST00000381668CPEB2chr415009210+ATP8A1chr442509171-9.00E-050.99991
ENST00000442003ENST00000264449CPEB2chr415009210+ATP8A1chr442509171-9.13E-050.9999087
ENST00000538197ENST00000381668CPEB2chr415009210+ATP8A1chr442509171-0.0002402080.99975985
ENST00000538197ENST00000264449CPEB2chr415009210+ATP8A1chr442509171-0.0002422930.9997577
ENST00000541112ENST00000381668CPEB2chr415009210+ATP8A1chr442509171-0.0002402080.99975985
ENST00000541112ENST00000264449CPEB2chr415009210+ATP8A1chr442509171-0.0002422930.9997577
ENST00000507071ENST00000381668CPEB2chr415009210+ATP8A1chr442509171-0.0004409820.999559
ENST00000507071ENST00000264449CPEB2chr415009210+ATP8A1chr442509171-0.0004440450.9995559
ENST00000345451ENST00000381668CPEB2chr415009210+ATP8A1chr442509171-0.0004409820.999559
ENST00000345451ENST00000264449CPEB2chr415009210+ATP8A1chr442509171-0.0004440450.9995559
ENST00000259997ENST00000381668CPEB2chr415009210+ATP8A1chr442509171-0.0004330270.999567
ENST00000259997ENST00000264449CPEB2chr415009210+ATP8A1chr442509171-0.0004364780.9995635
ENST00000382401ENST00000381668CPEB2chr415009210+ATP8A1chr442509171-0.0004379850.99956197
ENST00000382401ENST00000264449CPEB2chr415009210+ATP8A1chr442509171-0.0004407690.9995592
ENST00000382395ENST00000381668CPEB2chr415009210+ATP8A1chr442509171-0.0004330270.999567
ENST00000382395ENST00000264449CPEB2chr415009210+ATP8A1chr442509171-0.0004364780.9995635

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for CPEB2-ATP8A1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
CPEB2chr415009210ATP8A1chr4425091711671557QQRNSYNHHQVRMNLQLLGATAIEDK
CPEB2chr415009210ATP8A1chr4425091711944647FRTDNNSNTLLPLQNLQLLGATAIED
CPEB2chr415009210ATP8A1chr442509171409120QQRNSYNHHQVRMNLQLLGATAIEDK
CPEB2chr415009210ATP8A1chr442509171682210FRTDNNSNTLLPLQNLQLLGATAIED
CPEB2chr415009210ATP8A1chr442509171720210FRTDNNSNTLLPLQNLQLLGATAIED

Top

Potential FusionNeoAntigen Information of CPEB2-ATP8A1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CPEB2-ATP8A1_15009210_42509171.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:06HHQVRMNL0.99960.6791715
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:01HHQVRMNL0.99960.7231715
CPEB2-ATP8A1chr415009210chr442509171409HLA-B38:02HHQVRMNL0.99930.8816715
CPEB2-ATP8A1chr415009210chr442509171409HLA-B38:01HHQVRMNL0.99930.8546715
CPEB2-ATP8A1chr415009210chr442509171682HLA-B51:01LPLQNLQL0.99410.50771018
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:03LPLQNLQL0.8950.85341018
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:02LPLQNLQL0.77420.93861018
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:04LPLQNLQL0.77420.93861018
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:01NHHQVRMNL0.9990.8369615
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:06NHHQVRMNL0.99830.6738615
CPEB2-ATP8A1chr415009210chr442509171409HLA-B38:02NHHQVRMNL0.99690.905615
CPEB2-ATP8A1chr415009210chr442509171409HLA-B38:01NHHQVRMNL0.99610.8811615
CPEB2-ATP8A1chr415009210chr442509171409HLA-B14:01NHHQVRMNL0.99470.5358615
CPEB2-ATP8A1chr415009210chr442509171409HLA-B14:02NHHQVRMNL0.99470.5358615
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:24HQVRMNLQL0.99140.5197817
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:03LPLQNLQLL0.98680.89831019
CPEB2-ATP8A1chr415009210chr442509171409HLA-B14:02HQVRMNLQL0.98290.8084817
CPEB2-ATP8A1chr415009210chr442509171409HLA-B14:01HQVRMNLQL0.98290.8084817
CPEB2-ATP8A1chr415009210chr442509171682HLA-B51:01LPLQNLQLL0.98040.53251019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:01LPLQNLQLL0.98020.84621019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:08LPLQNLQLL0.96930.89451019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B51:02LPLQNLQLL0.96110.51091019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:05LPLQNLQLL0.95330.68561019
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:01HQVRMNLQL0.94310.9135817
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:02LPLQNLQLL0.92390.9551019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:04LPLQNLQLL0.92390.9551019
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:04LLPLQNLQL0.90910.9097918
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:17LLPLQNLQL0.90520.82918
CPEB2-ATP8A1chr415009210chr442509171409HLA-B38:02HQVRMNLQL0.84720.9565817
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:13HQVRMNLQL0.84560.9376817
CPEB2-ATP8A1chr415009210chr442509171409HLA-B38:01HQVRMNLQL0.84560.9388817
CPEB2-ATP8A1chr415009210chr442509171409HLA-B15:18NHHQVRMNL0.82110.5603615
CPEB2-ATP8A1chr415009210chr442509171409HLA-B15:03HQVRMNLQL0.74080.6873817
CPEB2-ATP8A1chr415009210chr442509171409HLA-B13:02HQVRMNLQL0.710.6164817
CPEB2-ATP8A1chr415009210chr442509171409HLA-B13:01HQVRMNLQL0.65290.8877817
CPEB2-ATP8A1chr415009210chr442509171682HLA-B81:01LPLQNLQLL0.57250.55551019
CPEB2-ATP8A1chr415009210chr442509171409HLA-B15:37HQVRMNLQL0.49260.5074817
CPEB2-ATP8A1chr415009210chr442509171682HLA-B82:01LPLQNLQLL0.44460.69941019
CPEB2-ATP8A1chr415009210chr442509171409HLA-B07:10HQVRMNLQL0.27140.5393817
CPEB2-ATP8A1chr415009210chr442509171409HLA-B52:01HQVRMNLQL0.03930.7724817
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:01HHQVRMNLQL0.99710.9055717
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:24HHQVRMNLQL0.99650.6441717
CPEB2-ATP8A1chr415009210chr442509171409HLA-B38:02HHQVRMNLQL0.9940.9575717
CPEB2-ATP8A1chr415009210chr442509171409HLA-B38:01HHQVRMNLQL0.99350.9408717
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:22TLLPLQNLQL0.97940.7619818
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:11TLLPLQNLQL0.96080.7412818
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:24TLLPLQNLQL0.960.7084818
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:67TLLPLQNLQL0.960.7084818
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:30TLLPLQNLQL0.960.7084818
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:60TLLPLQNLQL0.95910.7087818
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:27TLLPLQNLQL0.9590.7922818
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:16TLLPLQNLQL0.95330.6574818
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:04TLLPLQNLQL0.94630.9058818
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:01YNHHQVRMNL0.94470.8592515
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:17TLLPLQNLQL0.93230.7898818
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:35TLLPLQNLQL0.85850.7178818
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:29TLLPLQNLQL0.81240.7078818
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:20TLLPLQNLQL0.80260.7126818
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:19TLLPLQNLQL0.77980.7677818
CPEB2-ATP8A1chr415009210chr442509171409HLA-B07:10HHQVRMNLQL0.40270.6141717
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:01NHHQVRMNLQL0.99880.8263617
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:24NHHQVRMNLQL0.99870.5059617
CPEB2-ATP8A1chr415009210chr442509171409HLA-B38:02NHHQVRMNLQL0.99730.8942617
CPEB2-ATP8A1chr415009210chr442509171409HLA-B38:01NHHQVRMNLQL0.99690.8881617
CPEB2-ATP8A1chr415009210chr442509171409HLA-B38:01HHQVRMNLQLL0.98980.8556718
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:04TLLPLQNLQLL0.97020.8935819
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:17TLLPLQNLQLL0.95990.8458819
CPEB2-ATP8A1chr415009210chr442509171409HLA-C07:05VRMNLQLL0.99970.94241018
CPEB2-ATP8A1chr415009210chr442509171409HLA-C07:95VRMNLQLL0.99970.59821018
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:09HHQVRMNL0.99960.5323715
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:12HHQVRMNL0.99950.7387715
CPEB2-ATP8A1chr415009210chr442509171409HLA-C07:27VRMNLQLL0.99950.91121018
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:05HHQVRMNL0.99910.7121715
CPEB2-ATP8A1chr415009210chr442509171682HLA-B51:08LPLQNLQL0.96730.58441018
CPEB2-ATP8A1chr415009210chr442509171682HLA-B42:02LPLQNLQL0.90290.92691018
CPEB2-ATP8A1chr415009210chr442509171409HLA-B14:03HHQVRMNL0.8870.597715
CPEB2-ATP8A1chr415009210chr442509171682HLA-B42:01LPLQNLQL0.88440.92241018
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:12LPLQNLQL0.77420.93861018
CPEB2-ATP8A1chr415009210chr442509171682HLA-B39:10LPLQNLQL0.52640.96581018
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:09NHHQVRMNL0.99920.557615
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:12NHHQVRMNL0.99870.8371615
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:05NHHQVRMNL0.99670.8217615
CPEB2-ATP8A1chr415009210chr442509171682HLA-C15:06NTLLPLQNL0.99650.9233716
CPEB2-ATP8A1chr415009210chr442509171682HLA-B51:07LPLQNLQLL0.97760.97011019
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:09HQVRMNLQL0.97650.7991817
CPEB2-ATP8A1chr415009210chr442509171682HLA-B78:01LPLQNLQLL0.96180.70171019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B56:04LPLQNLQLL0.95060.52061019
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:12HQVRMNLQL0.94960.9215817
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:07LLPLQNLQL0.93040.7407918
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:12LPLQNLQLL0.92390.9551019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B51:08LPLQNLQLL0.9060.59341019
CPEB2-ATP8A1chr415009210chr442509171409HLA-B15:04HQVRMNLQL0.87780.7759817
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:05HQVRMNLQL0.850.9047817
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:08HQVRMNLQL0.82010.8633817
CPEB2-ATP8A1chr415009210chr442509171682HLA-C01:17LLPLQNLQL0.78560.9848918
CPEB2-ATP8A1chr415009210chr442509171409HLA-C07:13NHHQVRMNL0.76920.8151615
CPEB2-ATP8A1chr415009210chr442509171409HLA-C07:27NHHQVRMNL0.76890.9024615
CPEB2-ATP8A1chr415009210chr442509171682HLA-B39:10LPLQNLQLL0.75520.9741019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B42:02LPLQNLQLL0.7540.9591019
CPEB2-ATP8A1chr415009210chr442509171409HLA-C07:05NHHQVRMNL0.74040.9377615
CPEB2-ATP8A1chr415009210chr442509171409HLA-B14:03HQVRMNLQL0.73940.7953817
CPEB2-ATP8A1chr415009210chr442509171409HLA-C07:29NHHQVRMNL0.72670.9051615
CPEB2-ATP8A1chr415009210chr442509171682HLA-B42:01LPLQNLQLL0.71350.95571019
CPEB2-ATP8A1chr415009210chr442509171682HLA-C01:30LLPLQNLQL0.69750.9789918
CPEB2-ATP8A1chr415009210chr442509171409HLA-C07:46NHHQVRMNL0.66870.7351615
CPEB2-ATP8A1chr415009210chr442509171409HLA-C07:19NHHQVRMNL0.62040.5834615
CPEB2-ATP8A1chr415009210chr442509171409HLA-C07:80NHHQVRMNL0.61020.8548615
CPEB2-ATP8A1chr415009210chr442509171409HLA-C07:67NHHQVRMNL0.61020.8548615
CPEB2-ATP8A1chr415009210chr442509171409HLA-C07:10NHHQVRMNL0.60710.881615
CPEB2-ATP8A1chr415009210chr442509171409HLA-B14:03NHHQVRMNL0.54790.7296615
CPEB2-ATP8A1chr415009210chr442509171409HLA-B73:01NHHQVRMNL0.27380.5381615
CPEB2-ATP8A1chr415009210chr442509171409HLA-C12:16NHHQVRMNL0.0620.9518615
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:09HHQVRMNLQL0.99730.7826717
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:12HHQVRMNLQL0.99620.9148717
CPEB2-ATP8A1chr415009210chr442509171409HLA-B73:01VRMNLQLLGA0.99610.78191020
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:05HHQVRMNLQL0.99420.8967717
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:02TLLPLQNLQL0.98150.7689818
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:01TLLPLQNLQL0.960.7084818
CPEB2-ATP8A1chr415009210chr442509171409HLA-B14:03HHQVRMNLQL0.7580.802717
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:12NHHQVRMNLQL0.99850.8333617
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:09NHHQVRMNLQL0.99830.6495617
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:05NHHQVRMNLQL0.99590.8069617
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:31HHQVRMNL0.99960.7364715
CPEB2-ATP8A1chr415009210chr442509171409HLA-B38:05HHQVRMNL0.99930.8546715
CPEB2-ATP8A1chr415009210chr442509171682HLA-B78:02LPLQNLQL0.99330.66821018
CPEB2-ATP8A1chr415009210chr442509171409HLA-C06:08VRMNLQLL0.9920.98561018
CPEB2-ATP8A1chr415009210chr442509171682HLA-B51:09LPLQNLQL0.97990.50071018
CPEB2-ATP8A1chr415009210chr442509171682HLA-B51:21LPLQNLQL0.97960.54671018
CPEB2-ATP8A1chr415009210chr442509171409HLA-C06:02VRMNLQLL0.93530.98991018
CPEB2-ATP8A1chr415009210chr442509171409HLA-C06:17VRMNLQLL0.93530.98991018
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:13LPLQNLQL0.92850.85981018
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:11HHQVRMNL0.91540.6535715
CPEB2-ATP8A1chr415009210chr442509171682HLA-B55:04LPLQNLQL0.81660.52811018
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:09LPLQNLQL0.77420.93861018
CPEB2-ATP8A1chr415009210chr442509171682HLA-B67:01LPLQNLQL0.58640.85141018
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:31NHHQVRMNL0.9990.8351615
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:02NHHQVRMNL0.99860.8516615
CPEB2-ATP8A1chr415009210chr442509171409HLA-B38:05NHHQVRMNL0.99610.8811615
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:13LPLQNLQLL0.98670.90471019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B78:02LPLQNLQLL0.98260.7361019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:23LPLQNLQLL0.98130.87881019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:77LPLQNLQLL0.98020.84621019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B51:09LPLQNLQLL0.97340.50741019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B51:06LPLQNLQLL0.97030.54251019
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:02HQVRMNLQL0.96480.9351817
CPEB2-ATP8A1chr415009210chr442509171682HLA-B55:04LPLQNLQLL0.96320.61651019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:17LPLQNLQLL0.96320.75641019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:30LPLQNLQLL0.96320.75641019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B59:01LPLQNLQLL0.95940.52491019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:22LPLQNLQLL0.95670.56581019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B56:02LPLQNLQLL0.95060.52061019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:24LPLQNLQLL0.94860.80961019
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:31HQVRMNLQL0.94850.917817
CPEB2-ATP8A1chr415009210chr442509171682HLA-B51:21LPLQNLQLL0.93130.56261019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:09LPLQNLQLL0.92390.9551019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B53:02LPLQNLQLL0.91490.51781019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:11LPLQNLQLL0.90750.88321019
CPEB2-ATP8A1chr415009210chr442509171682HLA-A68:02NTLLPLQNL0.90290.7547716
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:11NHHQVRMNL0.86660.7695615
CPEB2-ATP8A1chr415009210chr442509171682HLA-A69:01NTLLPLQNL0.85310.7012716
CPEB2-ATP8A1chr415009210chr442509171409HLA-B38:05HQVRMNLQL0.84560.9388817
CPEB2-ATP8A1chr415009210chr442509171409HLA-B15:73HQVRMNLQL0.83320.8917817
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:11HQVRMNLQL0.78590.8222817
CPEB2-ATP8A1chr415009210chr442509171682HLA-C01:02LLPLQNLQL0.7850.9843918
CPEB2-ATP8A1chr415009210chr442509171682HLA-B67:01LPLQNLQLL0.7850.88121019
CPEB2-ATP8A1chr415009210chr442509171409HLA-B15:54HQVRMNLQL0.76650.7676817
CPEB2-ATP8A1chr415009210chr442509171409HLA-B15:68HQVRMNLQL0.75110.5188817
CPEB2-ATP8A1chr415009210chr442509171409HLA-C07:22NHHQVRMNL0.74650.6969615
CPEB2-ATP8A1chr415009210chr442509171409HLA-A02:14HQVRMNLQL0.73430.569817
CPEB2-ATP8A1chr415009210chr442509171409HLA-C07:17NHHQVRMNL0.73310.9438615
CPEB2-ATP8A1chr415009210chr442509171682HLA-C01:03LLPLQNLQL0.72360.9885918
CPEB2-ATP8A1chr415009210chr442509171409HLA-B15:30HQVRMNLQL0.68330.8556817
CPEB2-ATP8A1chr415009210chr442509171409HLA-C07:04NHHQVRMNL0.68290.9149615
CPEB2-ATP8A1chr415009210chr442509171409HLA-B48:02HQVRMNLQL0.64970.8574817
CPEB2-ATP8A1chr415009210chr442509171409HLA-C07:02NHHQVRMNL0.61020.8548615
CPEB2-ATP8A1chr415009210chr442509171682HLA-B08:12LPLQNLQLL0.58480.97051019
CPEB2-ATP8A1chr415009210chr442509171682HLA-B82:02LPLQNLQLL0.44460.69941019
CPEB2-ATP8A1chr415009210chr442509171409HLA-B15:09HQVRMNLQL0.35810.5394817
CPEB2-ATP8A1chr415009210chr442509171409HLA-B15:20HQVRMNLQL0.34770.8611817
CPEB2-ATP8A1chr415009210chr442509171409HLA-B35:28HQVRMNLQL0.33830.8702817
CPEB2-ATP8A1chr415009210chr442509171682HLA-B40:21LLPLQNLQL0.07890.6268918
CPEB2-ATP8A1chr415009210chr442509171682HLA-B35:43LPLQNLQLL0.02990.83451019
CPEB2-ATP8A1chr415009210chr442509171409HLA-B38:05HHQVRMNLQL0.99350.9408717
CPEB2-ATP8A1chr415009210chr442509171682HLA-A02:14TLLPLQNLQL0.95480.8237818
CPEB2-ATP8A1chr415009210chr442509171682HLA-C01:02LLPLQNLQLL0.94380.9865919
CPEB2-ATP8A1chr415009210chr442509171409HLA-B15:09HHQVRMNLQL0.89950.5412717
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:11HHQVRMNLQL0.84730.8193717
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:31NHHQVRMNLQL0.99850.8275617
CPEB2-ATP8A1chr415009210chr442509171409HLA-B38:05NHHQVRMNLQL0.99690.8881617
CPEB2-ATP8A1chr415009210chr442509171409HLA-B38:05HHQVRMNLQLL0.98980.8556718
CPEB2-ATP8A1chr415009210chr442509171409HLA-B15:09NHHQVRMNLQL0.96620.5404617
CPEB2-ATP8A1chr415009210chr442509171409HLA-B39:11NHHQVRMNLQL0.93410.765617

Top

Potential FusionNeoAntigen Information of CPEB2-ATP8A1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CPEB2-ATP8A1_15009210_42509171.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CPEB2-ATP8A1chr415009210chr442509171409DRB1-0101RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-0102RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-0102VRMNLQLLGATAIED1025
CPEB2-ATP8A1chr415009210chr442509171409DRB1-0105RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-0107RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-0109RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-0111RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-0117RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-0119RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-0121RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-0123RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-0123VRMNLQLLGATAIED1025
CPEB2-ATP8A1chr415009210chr442509171409DRB1-0125RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-0127RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-0129RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-0131RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-1201RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-1203RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-1205RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-1206RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-1207RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-1210RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-1211RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-1212RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-1214RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-1216RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-1217RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-1219RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-1221RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171409DRB1-1222RMNLQLLGATAIEDK1126
CPEB2-ATP8A1chr415009210chr442509171682DRB1-1615SNTLLPLQNLQLLGA621
CPEB2-ATP8A1chr415009210chr442509171682DRB1-1615NSNTLLPLQNLQLLG520

Top

Fusion breakpoint peptide structures of CPEB2-ATP8A1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
6178NHHQVRMNLQLLGACPEB2ATP8A1chr415009210chr442509171409
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
8871SNTLLPLQNLQLLGCPEB2ATP8A1chr415009210chr442509171682

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of CPEB2-ATP8A1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN6178NHHQVRMNLQLLGA-7.9962-8.1096
HLA-B14:023BVN6178NHHQVRMNLQLLGA-5.70842-6.74372
HLA-B52:013W396178NHHQVRMNLQLLGA-6.83737-6.95077
HLA-B52:013W396178NHHQVRMNLQLLGA-4.4836-5.5189
HLA-A11:014UQ26178NHHQVRMNLQLLGA-10.0067-10.1201
HLA-A11:014UQ26178NHHQVRMNLQLLGA-9.03915-10.0745
HLA-A24:025HGA6178NHHQVRMNLQLLGA-6.56204-6.67544
HLA-A24:025HGA6178NHHQVRMNLQLLGA-5.42271-6.45801
HLA-B44:053DX86178NHHQVRMNLQLLGA-7.85648-8.89178
HLA-B44:053DX86178NHHQVRMNLQLLGA-5.3978-5.5112
HLA-A02:016TDR6178NHHQVRMNLQLLGA-3.37154-4.40684
HLA-B14:023BVN8871SNTLLPLQNLQLLG-7.9962-8.1096
HLA-B14:023BVN8871SNTLLPLQNLQLLG-5.70842-6.74372
HLA-B52:013W398871SNTLLPLQNLQLLG-6.83737-6.95077
HLA-B52:013W398871SNTLLPLQNLQLLG-4.4836-5.5189
HLA-A11:014UQ28871SNTLLPLQNLQLLG-10.0067-10.1201
HLA-A11:014UQ28871SNTLLPLQNLQLLG-9.03915-10.0745
HLA-A24:025HGA8871SNTLLPLQNLQLLG-6.56204-6.67544
HLA-A24:025HGA8871SNTLLPLQNLQLLG-5.42271-6.45801
HLA-B44:053DX88871SNTLLPLQNLQLLG-7.85648-8.89178
HLA-B44:053DX88871SNTLLPLQNLQLLG-5.3978-5.5112
HLA-A02:016TDR8871SNTLLPLQNLQLLG-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of CPEB2-ATP8A1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
CPEB2-ATP8A1chr415009210chr4425091711018LPLQNLQLCCCTTACAGAATCTTCAGCTACTT
CPEB2-ATP8A1chr415009210chr4425091711018VRMNLQLLGTAAGAATGAATCTTCAGCTACTT
CPEB2-ATP8A1chr415009210chr4425091711019LPLQNLQLLCCCTTACAGAATCTTCAGCTACTTGGA
CPEB2-ATP8A1chr415009210chr4425091711020VRMNLQLLGAGTAAGAATGAATCTTCAGCTACTTGGAGCA
CPEB2-ATP8A1chr415009210chr442509171515YNHHQVRMNLTATAACCACCACCAGGTAAGAATGAATCTT
CPEB2-ATP8A1chr415009210chr442509171615NHHQVRMNLAACCACCACCAGGTAAGAATGAATCTT
CPEB2-ATP8A1chr415009210chr442509171617NHHQVRMNLQLAACCACCACCAGGTAAGAATGAATCTTCAGCTA
CPEB2-ATP8A1chr415009210chr442509171715HHQVRMNLCACCACCAGGTAAGAATGAATCTT
CPEB2-ATP8A1chr415009210chr442509171716NTLLPLQNLACACTCTTACCCTTACAGAATCTTCAG
CPEB2-ATP8A1chr415009210chr442509171717HHQVRMNLQLCACCACCAGGTAAGAATGAATCTTCAGCTA
CPEB2-ATP8A1chr415009210chr442509171718HHQVRMNLQLLCACCACCAGGTAAGAATGAATCTTCAGCTACTT
CPEB2-ATP8A1chr415009210chr442509171817HQVRMNLQLCACCAGGTAAGAATGAATCTTCAGCTA
CPEB2-ATP8A1chr415009210chr442509171818TLLPLQNLQLCTCTTACCCTTACAGAATCTTCAGCTACTT
CPEB2-ATP8A1chr415009210chr442509171819TLLPLQNLQLLCTCTTACCCTTACAGAATCTTCAGCTACTTGGA
CPEB2-ATP8A1chr415009210chr442509171918LLPLQNLQLTTACCCTTACAGAATCTTCAGCTACTT
CPEB2-ATP8A1chr415009210chr442509171919LLPLQNLQLLTTACCCTTACAGAATCTTCAGCTACTTGGA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
CPEB2-ATP8A1chr415009210chr4425091711025VRMNLQLLGATAIEDGTAAGAATGAATCTTCAGCTACTTGGAGCAACAGCCATTGAGGAT
CPEB2-ATP8A1chr415009210chr4425091711126RMNLQLLGATAIEDKAGAATGAATCTTCAGCTACTTGGAGCAACAGCCATTGAGGATAAA
CPEB2-ATP8A1chr415009210chr442509171520NSNTLLPLQNLQLLGAGTAATACACTCTTACCCTTACAGAATCTTCAGCTACTTGGAGCA
CPEB2-ATP8A1chr415009210chr442509171621SNTLLPLQNLQLLGAAATACACTCTTACCCTTACAGAATCTTCAGCTACTTGGAGCAACA

Top

Information of the samples that have these potential fusion neoantigens of CPEB2-ATP8A1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
STADCPEB2-ATP8A1chr415009210ENST00000259997chr442509171ENST00000264449TCGA-HU-8244-01A
STADCPEB2-ATP8A1chr415009210ENST00000382401chr442509171ENST00000264449TCGA-HU-8244-01A

Top

Potential target of CAR-T therapy development for CPEB2-ATP8A1

check button Predicted 3D structure. We used RoseTTAFold.
120_CPEB2-ATP8A1_t000_.e2e.pdb


check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
TgeneATP8A1chr4:15009210chr4:42509171ENST0000026444920361006_102601150.0TransmembraneHelical
TgeneATP8A1chr4:15009210chr4:42509171ENST0000026444920361045_107001150.0TransmembraneHelical
TgeneATP8A1chr4:15009210chr4:42509171ENST000002644492036858_87801150.0TransmembraneHelical
TgeneATP8A1chr4:15009210chr4:42509171ENST000002644492036891_91001150.0TransmembraneHelical
TgeneATP8A1chr4:15009210chr4:42509171ENST000002644492036941_96201150.0TransmembraneHelical
TgeneATP8A1chr4:15009210chr4:42509171ENST0000038166821371006_102601165.0TransmembraneHelical
TgeneATP8A1chr4:15009210chr4:42509171ENST0000038166821371045_107001165.0TransmembraneHelical
TgeneATP8A1chr4:15009210chr4:42509171ENST000003816682137858_87801165.0TransmembraneHelical
TgeneATP8A1chr4:15009210chr4:42509171ENST000003816682137891_91001165.0TransmembraneHelical
TgeneATP8A1chr4:15009210chr4:42509171ENST000003816682137941_96201165.0TransmembraneHelical

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result
CPEB2chr415009210ENST00000259997ATP8A1chr442509171ENST00000264449
CPEB2chr415009210ENST00000382401ATP8A1chr442509171ENST00000264449
CPEB2chr415009210ENST00000442003ATP8A1chr442509171ENST00000264449
CPEB2chr415009210ENST00000538197ATP8A1chr442509171ENST00000264449

Top

Related Drugs to CPEB2-ATP8A1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to CPEB2-ATP8A1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource